Hyderabad’s Ceremorphic Unveils Life Sciences Division

The new division will leverage its own proprietary analogue and Al technology on its advanced digital platform to develop new drugs with new levels of efficiency in the entire development pipeline.

Hyderabad’s development centre, Ceremorphic, has launched a new life sciences division called ‘Ceremorphic Life Sciences’.

The new division will leverage its own proprietary analogue and Al technology on its advanced digital platform to develop new drugs with new levels of efficiency in the entire development pipeline.

The division aims to address one of the biggest challenges in the pharma and biotech sector which is the cost and time-consuming process of drug discovery.

Reportedly, there are more than 10,000 diseases in the world and only 500 drugs are available today to close the gap, Ceremorphic Life Sciences has designed a platform called BioCompDiscoverX, that can speed up every phase of discovery and development and selectivity at every stage.

Moreover, it is based on Ceremorphic's proprietary patent-pending technologies and includes a hardware-software solution leveraging its advanced silicon technology.

The BioCompDiscoverX strives to enhance scalability by minimising wet lab usage as much as possible and leverages the power of analogue and Al technology.

Additionally, Ceremorphic's hybrid approach utilises analogue to accelerate computation speed and also empowers Al to be highly effective throughout the entire development process.

Sharing his views, Dr Venkat Mattela, founder and CEO, Ceremorphic, said "One new drug today typically requires over 10 years to develop, which can easily cost a pharma company more than $2 billion to bring to market. ’In addition to the cost the drug development throughput and the balance of safety and efficacy are sub-optimal. This is going to change with Ceremorphic Life Sciences' new design methodology because we have developed a new platform that can speed every single phase of discovery and development and selectivity at every stage. This type of platform has been long considered the holy grail of drug development and we are making it a reality that can transform the entire pharmaceutical industry for the benefit of all of society.’’

Founded in 2020, by Dr Venkat Mattela, Ceremorphic is a development centre in Hyderabad. It is a division of Ceremorphic Inc. which is based in San Jose, US. The life sciences division was established to transform the entire drug discovery and development process.

Currently, the team at this centre is working towards designing a supercomputing chip with higher reliability and energy efficiency. Further, Ceremorphic aims to deliver a complete silicon system that will enable next-generation applications such as AI, ML, high-power computing (HPC), automotive processing, drug discovery, and metaverse processing.

Talking about life sciences, Just a few days back, US-based NextGen Genetics launched Genetic Testing Services in collaboration with Luminary Life Sciences. The new entity, Luminary Genetics, will further invest in research and development as well as in advanced technologies to enable a continued focus on customer service and genetic counselling.